MOMI, Stefania
 Distribuzione geografica
Continente #
NA - Nord America 1.496
EU - Europa 1.102
AS - Asia 504
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 3.105
Nazione #
US - Stati Uniti d'America 1.492
IE - Irlanda 270
UA - Ucraina 248
IT - Italia 198
SG - Singapore 171
HK - Hong Kong 134
SE - Svezia 116
VN - Vietnam 83
CN - Cina 80
FI - Finlandia 64
RU - Federazione Russa 61
DE - Germania 54
GB - Regno Unito 36
FR - Francia 13
TR - Turchia 11
BE - Belgio 9
KR - Corea 8
CH - Svizzera 6
UZ - Uzbekistan 5
AT - Austria 4
LB - Libano 4
CA - Canada 3
CZ - Repubblica Ceca 3
ES - Italia 3
PL - Polonia 3
RO - Romania 3
BG - Bulgaria 2
GR - Grecia 2
IR - Iran 2
PH - Filippine 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
CR - Costa Rica 1
EU - Europa 1
HU - Ungheria 1
IN - India 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
MK - Macedonia 1
NL - Olanda 1
NO - Norvegia 1
TW - Taiwan 1
Totale 3.105
Città #
Chandler 326
Dublin 265
San Mateo 146
Jacksonville 139
Hong Kong 134
Singapore 129
Dong Ket 83
Boardman 80
Perugia 78
Altamura 77
Santa Clara 68
Medford 63
Princeton 63
Lawrence 57
Ann Arbor 51
Wilmington 51
Beijing 32
Andover 29
Des Moines 27
Saint Petersburg 21
Dearborn 17
San Paolo di Civitate 12
Woodbridge 12
Izmir 11
Helsinki 10
Los Angeles 10
New York 10
Brussels 9
Norwalk 9
Ashburn 8
Seoul 8
Shanghai 6
Dallas 5
Munich 5
Auburn Hills 4
Falls Church 4
Moscow 4
Amelia 3
Madrid 3
Menlo Park 3
Olomouc 3
Ottawa 3
Rome 3
Southwark 3
Espoo 2
Granarolo dell'Emilia e Viadagola 2
Gubbio 2
Houston 2
Ludwigshafen 2
Narni 2
Newton Stewart 2
Parma 2
Redwood City 2
San Diego 2
Siegen 2
Sofia 2
Timisoara 2
Ugong Norte 2
Alameda 1
Almaty 1
Bucharest 1
Clearwater 1
Colombo 1
Corciano 1
Den Haag 1
Falkenstein 1
Frankfurt Am Main 1
Fuzhou 1
Hebei 1
Jinan 1
Kiev 1
Lausanne 1
Logan 1
London 1
Milan 1
New Orleans 1
Philadelphia 1
Redmond 1
San José 1
Sopron 1
Taipei 1
Vancouver 1
Vijayawada 1
Vilnius 1
Wuhan 1
Zurich 1
Totale 2.140
Nome #
Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation. No effect of aspirin intake. 88
RhoA signaling through platelet P2Y1 receptor controls leukocyte recruitment in allergic mice. 86
Nitric oxide and its antithrombotic action on the cardiovascular system 83
Platelets are essential for leukocyte recruitment in allergic inflammation. 83
Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. 82
Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome. 74
Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives. 72
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. 71
Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation 69
A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling 68
Anti-platelet therapy: phosphodiesterase inhibitors. 67
Contribution of matrix metalloproteinase 2 to joint destruction in group B Streptococcus-induced murine arthritis. 65
Matrix metalloproteinases and peripheral arterial disease. 64
A novel nitric oxide-releasing statin derivative exerts and antiplatelet/antithrombotic activity and inhibits tissue factor expression. 64
Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. 64
Defective platelet beta-N-Acetyl hexosaminidase content and release in chronic myeloproliferative disorders 63
Allergen induces the migration of platelets to lung tissue in allergic asthma. 61
Mechanisms of thrombocytopenia in platelet-type von Willebrand disease 61
Endothelium, venous thromboembolism and ischaemic cardiovascular events. 58
Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. 57
Platelets contribute to the accumulation of matrix metalloproteinase type 2 in synovial fluid in osteoarthritis 56
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. 55
Established and new antiplatelet therapies 54
Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. 53
Chemotaxis and phagocytosis 53
AB0952 Intra-articular low molecular weight hyaluronate reduces platelet influx and matrix metalloproteinase-2 levels in synovial fluid of patients with knee osteoarthritis 53
Platelet Priming. 52
Anti-platelet treatments in cancer: Basic and clinical research 52
Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. Correlation with ischaemic events. 51
Visualization of nitric oxide production by individual platelets during adhesion in flowing blood. 50
Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. 49
Matrix metalloproteinase-2 enhances platelet deposition on collagen under flow conditions 48
Platelet-targeted pharmacologic treatments as anti-cancer therapy 48
Involvement of platelets in experimental mouse trypanosomiasis: evidence of mouse platelet cytotoxicity against Trypanosoma equiperdum. 47
A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. 47
Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. 47
Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. 46
NCX4016: a novel antithrombotic agent. 46
Prevalence of hemostatic alterations in patients with recurrent spontaneous subconjunctival hemorrhage 46
A dichotomy in platelet activation: Evidence of different functional platelet responses to inflammatory versus haemostatic stimuli 46
Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies. 45
Low molecular weight heparins prevent thrombin-induced thromboembolism in mice despite low antithrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. 44
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice 43
HYPERGLYCEMIA-INDUCED PLATELET ACTIVATION IN TYPE 2 DIABETES MELLITUS IS RESISTANT TO ASPIRIN BUT NOT TO A NITRIC OXIDE-DONATING AGENT. 42
Trombocitopenia da eparina nel paziente dializzato 42
Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. 42
Highly Active Antiretroviral Therapy-related Mechanisms of Endothelial and Platelets Function Alterations 41
Matrix Metalloproteinases and Platelet Function 40
Nitric oxide-enhancing or -releasing agents as antithrombotic drugs. 40
Platelets in respiratory disorders and inflammatory conditions. 39
Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca(2+)-dependent tyrosine kinase Pyk2. 39
NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. 37
Platelets and chemotaxis. 35
Role of Platelets in the Pathogenesis of Osteoarthritis and Biological Effects of Hyaluronic Acid: in Vivo and in Vitro Study 35
The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits 34
Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. 33
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention 32
Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. 31
Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. 31
Matrix metalloproteinase-2 on activated platelets triggers endothelial PAR-1 initiating atherosclerosis 27
Stroke prevention: from available antiplatelet drugs to novel molecular targets. 25
Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis. 22
Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway 21
Totale 3.219
Categoria #
all - tutte 14.626
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.626


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020164 0 0 0 0 0 13 40 11 44 27 6 23
2020/2021522 4 34 14 40 156 24 44 2 51 15 46 92
2021/2022507 12 110 12 26 9 10 7 147 7 19 69 79
2022/20231.002 70 232 10 71 78 104 0 48 338 3 30 18
2023/2024381 19 42 18 5 2 4 99 9 46 12 77 48
2024/2025284 6 78 34 28 107 31 0 0 0 0 0 0
Totale 3.219